Trinity Biotech PLC
TRIB- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0000888721
No open-market purchases or sales by Trinity Biotech PLC insiders were filed in the last 90 days; 20 institutions reported holding it in 13F filings for Q2 2026, worth $379.5K in total; no superinvestor holds it.
Q1 2025 vs. Q4 2024
How the institutions holding Trinity Biotech PLC changed between Q4 2024 and Q1 2025.
All holders in Q1 2025All holders in Q4 2024
| Measure | Q4 2024 | Q1 2025 | Change |
|---|---|---|---|
| Holders | 23 | 27 | +4 |
| Shares | 2.61M | 821.8K | −1.79M (−68.5%) |
| Value | $2.30M | $468.1K | −$1.83M (−79.7%) |
New holders (8)
Institutions that held Trinity Biotech PLC at the end of Q1 2025 but not at the end of Q4 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| HRT Financial LP | 66,242 | $37.0K | 0.00% |
| Citadel Advisors LLC | 41,539 | $23.7K | 0.00% |
| Williams & Novak, LLC | 18,200 | $10.4K | 0.01% |
| Two Sigma Securities, LLC | 17,547 | $10.0K | 0.00% |
| Two Sigma Investments, LP | 15,073 | $8.59K | 0.00% |
| Advisor Group Holdings, Inc. | 4,500 | $2.56K | 0.00% |
| Farther Finance Advisors, LLC | 2,000 | $1.14K | 0.00% |
| SBI Securities Co., Ltd. | 10 | $6 | 0.00% |
Sold out (4)
Institutions that held Trinity Biotech PLC at the end of Q4 2024 and filed for Q1 2025 without it.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| Perceptive Advisors LLC | 1,790,000 | $1.58M |
| Susquehanna International Group, LLP | 12,483 | $11.0K |
| UBS Group AG | 10,621 | $9.35K |
| Clearstead Advisors, LLC | 10,000 | $8.80K |